The Bay Area Tumor Institute Community Clinical Oncology Program (BATI-CCOP) is a consortium of 7 community and county hospitals in Greater Oakland, California. Since its creation in 1979 as a CGOP and its convention to CCOP status in 1989, this consortium has continuously provided the community's cancer specialists, primary care physicians, and hospitals with an NCI-approved and funded clinical trials program. Integrating the goals of DHHS publication """"""""Healthy People 2010"""""""" by targeting minority, low income and female populations in Alameda County and its main city, Oakland, the BATI-CCOP enables cancer patients and the general """"""""at risk"""""""" population to participate in clinical and cancer control research of SWOG, NSABP, RTOG, COG, HLMCC and CCCWFU. Building on its achievements, the long-term objectives and specific aims of the BATI-CCOP include accrual to therapeutic trials at higher rates than comparable CCOPs, accrual of minority and pediatric patients at higher rates than all other CCOPs, aggressive cancer control recruitment and accrual exceeding NCI's cancer control research reequirements, increased interaction with research bases, and continued fulfillment of NCI's """"""""Terms and Conditions"""""""". The CCOP will continue to accrue 95% of all eligible pediatric oncology patients in the region and will continue to excel in the recruitment of minority and female participants essentially meeting the requirements of a Minority-Based CCOP, a Pediatric CCOP and an Adult CCOP. The CCOP will also continue to exceed NCI mandates and remain the Bay Area leader in accrual to cancer prevention and control trials. The BATI-CCOP offers a successful long-term track record, an organized and committed medical community, experienced physician investigators, institutional and financial support from the Bay Area Tumor Institute, and unusual access to African American, Hispanic, Asian, pediatric, underserved, and female populations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA045461-21
Application #
7845068
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
Mccaskill-Stevens, Worta J
Project Start
1993-06-25
Project End
2012-05-31
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
21
Fiscal Year
2010
Total Cost
$461,201
Indirect Cost
Name
Bay Area Tumor Institute
Department
Type
DUNS #
040003402
City
Oakland
State
CA
Country
United States
Zip Code
94609
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Kim, Edward S; Moon, James; Herbst, Roy S et al. (2013) Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol 8:1519-28
Smalley, Stephen R; Benedetti, Jacqueline K; Haller, Daniel G et al. (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-33
Schott, Anne F; Barlow, William E; Albain, Kathy S et al. (2012) Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist 17:179-87

Showing the most recent 10 out of 54 publications